Rocket Pharmaceuticals, Inc. Accumulated Other Comprehensive Income
Rocket Pharmaceuticals, Inc. (RCKT) had Accumulated Other Comprehensive Income of -$106.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-10
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$106.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$112.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$31.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$9.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | -$106.00K 10-Q · filed 2026-08-10 | |
| 2026-03-31 | -$112.00K 10-Q · filed 2026-05-07 | |
| 2025-12-31 | -$31.00K 10-Q · filed 2026-08-10 | |
| 2025-09-30 | -$9.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$107.00K 10-Q · filed 2025-08-07 | |
| 2025-03-31 | -$27.00K 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $66.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | $213.00K 10-Q · filed 2024-11-07 | |
| 2024-06-30 | -$218.00K 10-Q · filed 2024-08-06 | |
| 2024-03-31 | -$135.00K 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $319.00K 10-K · filed 2025-02-27 | |
| 2023-09-30 | -$508.00K 10-Q · filed 2023-11-07 | |
| 2023-06-30 | -$722.00K 10-Q · filed 2023-08-09 | |
| 2023-03-31 | -$90.00K 10-Q · filed 2023-05-05 | |
| 2022-12-31 | -$357.00K 10-K · filed 2024-02-27 | |
| 2022-09-30 | -$596.00K 10-Q · filed 2022-11-04 | |
| 2022-06-30 | -$765.00K 10-Q · filed 2022-08-09 | |
| 2022-03-31 | -$629.00K 10-Q · filed 2022-05-06 | |
| 2021-12-31 | -$161.00K 10-K · filed 2023-02-28 | |
| 2021-09-30 | -$97.00K 10-Q · filed 2021-11-05 | |
| 2021-06-30 | -$81.00K 10-Q · filed 2021-08-09 | |
| 2021-03-31 | -$75.00K 10-Q · filed 2021-05-10 | |
| 2020-12-31 | -$42.00K 10-K · filed 2022-02-28 | |
| 2020-09-30 | $69.00K 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $229.00K 10-Q · filed 2020-08-05 | |
| 2020-03-31 | -$75.00K 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $20.00K 10-K · filed 2021-03-01 | |
| 2019-09-30 | $117.00K 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $144.00K 10-Q · filed 2019-08-08 | |
| 2019-03-31 | -$89.00K 10-Q · filed 2019-05-09 | |
| 2018-12-31 | -$127.00K 10-K · filed 2020-03-06 | |
| 2018-09-30 | -$207.00K 10-Q · filed 2018-11-09 | |
| 2018-06-30 | -$79.00K 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $10.00K 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $0.00 10-K · filed 2019-03-08 | -$16.00K 10-K · filed 2018-03-07 |
| 2017-09-30 | -$25.00K 10-Q · filed 2017-11-08 | |
| 2017-06-30 | -$72.00K 10-Q · filed 2017-08-03 | |
| 2017-03-31 | -$72.00K 10-Q · filed 2017-05-10 | |
| 2016-12-31 | -$54.00K 10-K · filed 2018-03-07 | |
| 2016-09-30 | $2.00K 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $17.00K 10-Q · filed 2016-08-10 | |
| 2015-12-31 | -$11.00K 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |